Newsroom
Pediatric Praziquantel Consortium nominated for 2026 Prix Galien Bridges Award
The Pediatric Praziquantel Consortium has once again been nominated for the prestigious Prix Galien Bridges Award in the Best Public Sector Innovation category, recognising its achievement in developing a new treatment for schistosomiasis specifically designed for preschool-aged children.
The nomination, submitted by Lygature on behalf of the Consortium, marks the second consecutive year that this international public-private partnership has received recognition in this category.
Established in 2012 and concluded in 2026, the Pediatric Praziquantel Consortium brought together partners from academia, industry, public health and the non-profit sector to address a longstanding treatment gap for children aged 3 months to 6 years affected by schistosomiasis.
This latest nomination further acknowledges the achievements of the Consortium and the lasting impact of more than a decade of international collaboration.
The winners of the 2026 Prix Galien Bridges Awards will be announced at a ceremony on 1 December 2026 in Stockholm, Sweden.
For more information, read the Galien Foundation's official announcement.